Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETVAX with/without dmLT in Bangladesh
NCT02531802Phase 2Completed
- Sponsor
- PATH
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of oral tetravalent ETEC vaccine in enterotoxigenic Escherichia coli infection, sponsored by PATH. Started Oct 2015; status: completed.
02
Drugs
oral tetravalent ETEC vaccine
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT02531802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531802.